p53-Independent expression of p21(waf1/cip1) in preinvasive and invasive squamous neoplasms of the uterine cervix

Modern Pathology

Volumn 10, Issue 6, 1997, Pages 578-584

  Werness, Bruce A ^a   Wang, Hui Qun ^a   Chance, John ^b   Goldstein, David J ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

Cervical neoplasms; Cyclin dependent kinases; Ki 67; p53

Indexed keywords

CYCLIN DEPENDENT KINASE; KI 67 ANTIGEN; ONCOPROTEIN; PROTEIN P21; PROTEIN P53;

ARTICLE; CANCER INVASION; CELL PROLIFERATION; DNA DAMAGE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SQUAMOUS EPITHELIUM; TUMOR SUPPRESSOR GENE; UTERINE CERVIX TUMOR; WART VIRUS;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; ENZYME INHIBITORS; FEMALE; GENES, P53; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 0030737990     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Kurman RJ, Norris HJ, Wilkinson E. Tumors of the cervix. In: Rosai J, Sobin LH, editors. Tumors of the cervix, vagina, and vulva. Atlas of tumor pathology. 3rd series. Washington, D.C.: Armed Forces Institute of Pathology, 1992:44.
2. Park T-W, Fujiwara H, Wright TC. Molecular biology of cervical cancer and its precursors. Cancer 1995;76:1902-13.
3. Kessis TD, Slebos RJ, Nelson WG, Kastan MB Plunkett BS, Han SM, et al. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci U S A 1993;90:3988-92.
4. Slebos JC, Lee MH, Plunkett BS, Kessis TD, Williams BO, Jacks T, Hedrick L, Kastan MB, Cho KR p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci USA 1994;91:5320-4.
5. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63:1129-36.
6. Milde-Langosch K, Albrecht K, Joram S, Schlechte H, Giessing M. Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva. Int J Cancer 1995;63:639-45.
7. Kurvinen K, Tervahauta A, Syrjanen S, Chang F, Syrjanen K. The state of the p53 gene in human papillomavirus (HPV)-positive and HPV-negative genital precancer lesions and carcinomas as determined by single-strand conformation polymorphism analysis and sequencing. Anticancer Res 1994;14:177-81.
8. Busby-Earle RM, Steel CM, Williams AR, Cohen B, Bird CC. p53 mutations in cervical carcinogenesis: low frequency and lack of correlation with human papillomavirus status. Br J Cancer 1994;69:732-7.
9. Heiland A, Holm R, Kristensen G, Kaern J, Karlsen F, Trope C, et al. Genetic alterations of the TP53 gene, p53 protein expression, and HPV infection in primary cervical carcinomas. J Pathol 1993;171:105-14.
10. Chen TM, Chen CA, Hsieh CY, Chang DY, Chen YH, Defendi V. The state of p53 in primary human cervical carcinomas and its effects in human papillomavirus-immortalized human cervical cells. Oncogene 1993;8:1511-8.
11. Tsuda H, Hirohashi S. Frequent occurrence of p53 gene mutations in uterine cancers at advanced clinical stage and with aggressive histological phenotypes. Jpn J Cancer Res 1992;83:1184-91.
12. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
13. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukemia cells that is inhibited by interleukin-6. Nature 1991;352: 345-7.
14. Liu M, Pelling JC. UV-B/A irradiation of mouse keratinocytes results in p53-mediated waf1/cip1 expression. Oncogene 1995;10:1955-60.
15. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, et al. waf1/cip1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
16. waf1/CIP1 induces growth arrest, giant cell formation, and apoptosis in human breast carcinoma cell lines. Oncogene 1995;11:1899-905.
17. Skotzko M, Wu L, Anderson WF, Gordon EM, Hall FL. Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells. Cancer Res 1995;55:5493-8.
18. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995;55:5187-90.
19. Wright TC, Kurman RJ, Ferenczy A. Precancerous lesions of the cervix. In: Kurman RJ, editor. Blaustein's pathology of the female genital tract. 4th ed. New York, NY: Springer-Verlag, 1994:229-77.
20. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-5.
21. Levine AJ, Chang A, Dittmer D, Notterman DA, Silver A, Thorn K, et al. The p53 tumor suppressor gene. J Lab Clin Med 1994;123:817-23.
22. Iggo R, Gatter K, Bartek J, Lane D, Harris A. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;335:675-9.
23. Scheffner M, Münger K, Byrne JC, Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Nat Acad Sci USA 1991;88:5523-7.
24. Soini Y, Pollanen R, Kemppainen S, Paakko P, Lehto VP. The association of vascular proliferation with HPV status and epithelial PCNA positivity in cervical intraepithelial lesions. APMIS 1996;104:183-90.
25. Lukas Z, Vojtesek B, Anton M, Picksley SM, Kubalek V. Over-expression of p53 and MDM2 proteins in cervical neoplasia. Folia Biol 1995;41:197-9.
26. Mittal KR, Lin O, Chan W, Goswami S, Demopoulos RI. Cervical squamous dysplasias and carcinomas with immunodetectable p53 frequently contain HPV. Gynecol Oncol 1995;58:289-94.
27. Kainz C, Kohlberger P, Gitsch G, Sliutz G, Breitenecker G. Mutant p53 in patients with invasive cervical cancer stages IB to IIB. Gynecol Oncol 1995;57:212-4.
28. Akasofu M, Oda Y. Immunohistochemical detection of p53 in cervical epithelial lesions with or without infection of human papillomavirus types 16 and 18. Virch Archiv 1995; 425:593-602.
29. Vecchione A, Cermele C, Giovagnoli MR, Valli C, Alimandi M, Carico E, et al. p53 Expression and genetic evidence for viral infection in intraepithelial neoplasia of the uterine cervix. Gynecol Oncol 1994;55:343-8.
30. Tervahauta AI, Syrjanen SM, Mantyjarvi R, Syrjanen KJ. Detection of p53 protein and Ki-67 proliferation antigen in human papillomavirus (HPV)-positive and HPV-negative cervical lesions by immunohistochemical double-staining. Cytopathology 1994;5:282-93.
31. Inoue M, Fujita M, Enomoto T, Morimoto H, Monden T, Shimano T. Immunohistochemical analysis of p53 in gynecologic tumors. Am J Clin Pathol 1994;102:665-70.
32. Lambkin HA, Mothersill CM, Kelehan P. Variations in immunohistochemical detection of p53 protein overexpression in cervical carcinomas with different antibodies and methods of detection. J Pathol 1994;172:13-8.
33. Ngan HY, Stanley M, Liu SS, Ma HK. HPV and p53 in cervical cancer. Genitourin Med 1994;70:167-70.
34. Cardillo MR, Stamp GW, Pignatelli MN, Lalani EN. Immunohistochemical analysis of p53 oncoprotein and proliferating cell nuclear antigen (PCNA) in the cervix uteri. Eur J Gynecol Oncol 1993;14:484-90.
35. Holm R, Abeler VM, Skomedal H, Nesland JM. Overexpression of p53 protein and c-erbB-2 protein in small cell carcinoma of the cervix uteri. Zentralbl Pathol 1993;139:153-6.
36. Pollanen R, Soini Y, Vahakangas K, Paakko P, Lehto VP. Aberrant p53 protein expression in cervical intra-epithelial neoplasia. Histopathology 1993;23:471-4.
37. Walts AE, Koeffler HP, Said JW. Localization of p53 protein and human papillomavirus in anogenital squamous lesions: immunohistochemical and in situ hybridization studies in benign, dysplastic, and malignant epithelia. Hum Pathol 1993;24:1238-42.
38. Cooper K, Herrington CS, Evans MF, Gatter KC, McGee JO. p53 antigen in cervical condylomata, intraepithelial neoplasia, and carcinoma: relationship to HPV infection and integration. J Pathol 1993;171:27-34.
39. Bosari S, Roncalli M, Viale G, Bossi P, Coggi G. p53 Immunoreactivity in inflammatory and neoplastic diseases of the uterine cervix. J Pathol 1993;169:425-30.
40. Holm R, Skomedal H, Helland A, Kristensen G, Borresen AL, Nesland JM. Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri. J Pathol 1993;169:21-6.
41. Gitsch G, Kainz C, Joura E, Breitenecker G. Mutant p53 product in patients with stage III cervical cancer. Anticancer Res 1992;12:2241-2.
42. Finlay CA, Hinds PW, Tan T-H, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc-70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-9.
43. Daniel B, Mukherjee G, Seshadri L, Vallikad E, Krishna S. Changes in the physical state and expression of human papillomavirus 16 in the progression of cervical intraepitheliai neoplasia lesions analysed by PCR. J Gen Virol 1995;76: 2589-93.
44. Johnson M, Dimitrov D, Vojta PJ, Barrett JC, Noda A, Pereira-Smith OM, et al. Evidence for a p53-independent pathway for upregulation of SDI1/cip1/waf1/p21 RNA in human cells. Mol Carcinog 1994;11:59-64.
45. waf1 and p53 requires c-raf-1. Cancer Res 1995;55:4623-6.
46. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 1995;92:5545-9.
47. Missero C, Calautti E, Eckner R, Chin J, Tsai LH, Livingston DM. Involvement of the cell-cycle inhibitor cip1/waf1 and the E1A-associated p300 protein in terminal differentiation. Proc Natl Acad Sci U S A 1995;92:5451-5.
48. Zhang W, Grasso L, McClain CD, Gambel AM, Cha Y, Travali S, et al. p53-independent induction of waf1/cip1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 1995; 55:668-74.
49. Elbendary A, Berchuck A, Davis P, Havrilesky L, Bast RC Jr, Iglehart JD, et al. Transforming growth factor beta 1 can induce cip1/waf1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ 1994;5:1301-7.
50. Sheikh MS, Li XS, Chen JC, Shao ZM, Ordonez JV, Fontana JA. Mechanisms of regulation of waf1/cip1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene 1994;9: 3407-15.
51. Jiang H, Lin J, Su ZZ, Collart FR, Huberman E, Fisher PB. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, waf1/cip1, expression in the absence of p53. Oncogene 1994;9:3397-406.
52. waf1/cip1 in colorectal carcinoma. Br J Cancer 1996;74: 165-71.
53. Marchetti A, Doglioni C, Barbareschi M, Buttita F, Pellegrini S, Bertacca G, et al. p21 RNA and protein expression in non-small cell lung carcinoma: evidence of p53-independent expression and association with tumoral differentiation. Oncogene 1996;12:1319-24.
54. DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995;147: 884-8.
55. waf1/cip1 in malignant ovarian epithelial tumors and correlation with p53 and Ki-67 immunohistochemistry. Int J Gynecol Pathol 1997;16:149-55.
56. el-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, et al. Topological control of p21waf1/cip1 expression in normal and neoplastic tissues. Cancer Res 1995;55: 2910-9.
57. waf1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations, and relapse-free survival. Br J Cancer 1996;74:208-15.
58. Zedenius J, Larsson C, Wallin G, Backdahl M, Aspenblad U, Hoog A, et al.. Alterations of p53 and expression of waf1/p21 in human thyroid tumors. Thyroid 1996;6:1-9.
59. Ozcelik H, Mousses S, Andrulis IL. Low levels of expression of an inhibitor of cyclin-dependent kinases (cip1/waf1) in primary breast carcinomas with p53 mutations. Clin Cancer Res 1995;1:907-12.
60. waf1/cip1 in human brain tumors. Oncogene 1995;11:2021-8.
61. Papadaki H, Kounelis S, Kapadia SB, Bakker A, Swalsky PA, Finkelstein SD. Relationship of p53 gene alterations with tumor progression and recurrence in olfactory neuroblastoma. Am J Surg Pathol 1996;20:715-21.
62. Elbendery AA, Crisano FD, Evans AL Jr, Davis PL, Iglehart JD, Marks JR, et al. Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin Cancer Res 1996;2: 1571-5.
63. waf1/cip1 expression in the absence of p53. Oncogene 1994;9:3397-406.
64. waf1/cip1 during differentiation. Oncogene 1994;9:3389-96.
65. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. Transcriptional activation of the cdk inhibitor p21 by vitamin d-3 leads to the induced differentiation of the myelomonocytic cell line u937. Genes Dev 1996;10:142-53.
66. waf1 in human cutaneous squamous cell carcinoma. Am J Pathol 1996;149:1139-46.
67. Pierce GB, Wallace C. Differentiation of malignant to benign cells. Cancer Res 1971;31:127-34.